NMR in Infection Research



In comparison to other research areas, antibacterial drug discovery provides many opportunities to employ nuclear magnetic resonance (NMR) spectroscopy in the process of drug discovery. First of all, there are a large number of validated targets that can be cloned and expressed and their biological function is well understood. Most targets can be over-expressed readily and purified at quantities needed for NMR. Meanwhile, structural information is frequently available for at least one representative of a given target. Furthermore, enzyme substrates and corresponding inhibitors are often available and characterized. In combination, these factors make NMR studies for bacterial targets both feasible and economical in industrial research.


Nuclear Magnetic Resonance Nuclear Magnetic Resonance Spectroscopy Nuclear Magnetic Resonance Experiment Nuclear Overhauser Effect Nuclear Magnetic Resonance Method 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Betz M, Saxena K, Schwalbe H (2006) Biomolecular NMR: a chaperone to drug discovery. Curr Opin Chem Biol 10:219–225PubMedCrossRefGoogle Scholar
  2. 2.
    Cai M, Huang Y, Sakaguchi K et al (1998) An efficient and cost-effective isotope labeling protocol for proteins expressed in Escherichia coli. J Biomol NMR 11:97–102PubMedCrossRefGoogle Scholar
  3. 3.
    Cavanagh J, Fairbrother WJ, Palmer AG III et al (2006) Protein NMR spectroscopy: principles and practice. Elsevier Science, Technology, OxfordGoogle Scholar
  4. 4.
    Clore GM, Gronenborn AM (1982) Theory and applications of the transferred nuclear overhauser effect to the study of the conformations of small ligands bound to proteins. J Magn Reson 48:402–417CrossRefGoogle Scholar
  5. 5.
    Dalvit C, Pevarello P, Tato M et al (2000) Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR 18:65–68PubMedCrossRefGoogle Scholar
  6. 6.
    Dalvit C, Fogliatto G, Stewart A et al (2001) WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J Biomol NMR 21:349–359PubMedCrossRefGoogle Scholar
  7. 7.
    Emanuele JJJ, Jin H, Yanchunas J et al (1997) Evaluation of the kinetic mechanism of Escherichia coli uridine diphosphate-N-acetylmuramate: L-alanine ligase. Biochemistry 36:7264–7271PubMedCrossRefGoogle Scholar
  8. 8.
    Ernst RR, Bodenhausen G, Wokaun A (1990) Principles of nuclear magnetic resonance in one and two dimensions. Clarendon Press, 2004 ISBN 0198556470, 9780198556473Google Scholar
  9. 9.
    Fejzo J, Lepre CA, Peng JW et al (1999) The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol 6:755–769PubMedCrossRefGoogle Scholar
  10. 10.
    Gharbi-Benarous J, Evrard-Todeschi N, Ladam P et al (1999) Conformational analysis of josamycin, a 16-membered macrolide free in solution and bound to bacterial ribosomes. J Chem Soc Perkin Trans 2:529–544Google Scholar
  11. 11.
    Gossert AD, Henry C, Blommers MJJ et al (2009) Time efficient detection of protein-ligand interactions with the polarization optimized PO-WaterLOGSY NMR experiment. J Biomol NMR 43:211–217PubMedCrossRefGoogle Scholar
  12. 12.
    Hajduk PJ, Olejniczak ET, Fesik SW (1997) One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J Am Chem Soc 119:12257–12261CrossRefGoogle Scholar
  13. 13.
    Hajduk PJ, Mack JC, Olejniczak ET et al (2004) SOS-NMR: a saturation transfer NMR-based method for determining the structures of protein-ligand complexes. J Am Chem Soc 126:2390–2398PubMedCrossRefGoogle Scholar
  14. 14.
    Huang X, Lee MS (2004) NMR in drug discovery. Front Biotechnol Pharm 4:338–349Google Scholar
  15. 15.
    Jahnke W (2003) NMR in drug discovery. Chimia 57:59Google Scholar
  16. 16.
    Johnson EC, Feher VA, Peng JW et al (2003) Application of NMR SHAPES screening to an RNA target. J Am Chem Soc 125:15724–15725PubMedCrossRefGoogle Scholar
  17. 17.
    Lahiri S, Mills S (2006) Crystal structure of haemophilus influenzae NAD-dependent DNA ligase A and its uses for molecular modeling of substrate modulators. PCT Int Appl 2005-GB3125; 2004-600667, 90Google Scholar
  18. 18.
    Lepre CA, Moore JM, Peng JW (2004) Theory and applications of NMR-based screening in pharmaceutical research. Chem Rev 104:3641–3675 (Washington, DC, US)PubMedCrossRefGoogle Scholar
  19. 19.
    Levitt MH (2008) Spin dynamics: basics of nuclear magnetic resonance. Wiley, ChichesterGoogle Scholar
  20. 20.
    Lundqvist T et al (2007) Exploitation of structural and regulatory diversity in glutamate racemases. Nature 447:817–822PubMedCrossRefGoogle Scholar
  21. 21.
    Mayer M, Meyer B (1999) Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 38:1784–1788CrossRefGoogle Scholar
  22. 22.
    Mayer M, Meyer B (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123:6108–6117PubMedCrossRefGoogle Scholar
  23. 23.
    Palmer AGIII, Kroenke CD, Loria JP (2001) Nuclear magnetic resonance methods for quantifying microsecond-to-millisecond motions in biological macromolecules. Methods Enzymol 339:204–238PubMedCrossRefGoogle Scholar
  24. 24.
    Pervushin K, Riek R, Wider G et al (1997) Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc Natl Acad Sci USA 94:12366–12371PubMedCrossRefGoogle Scholar
  25. 25.
    Plesniak LA, Botsch K, Leibrand M et al (2008) Transferred NOE and saturation transfer difference NMR studies of novobiocin binding to EnvZ suggest binding mode similar to DNA gyrase. Chem Biol Drug Des 71:28–35PubMedGoogle Scholar
  26. 26.
    Pochapsky SS, Pochapsky TC (2001) Nuclear magnetic resonance as a tool in drug discovery, metabolism and disposition. Curr Top Med Chem 1:427–441 (Hilversum, Neth)PubMedCrossRefGoogle Scholar
  27. 27.
    Powers R (2009) Advances in nuclear magnetic resonance for drug discovery. Expert Opin Drug Discov 4:1077–1098PubMedCrossRefGoogle Scholar
  28. 28.
    Sanders CR, Sonnichsen F (2006) Solution NMR of membrane proteins: practice and challenges. Magn Reson Chem 44:S24–S40PubMedCrossRefGoogle Scholar
  29. 29.
    Sprangers R, Kay LE (2007) Quantitative dynamics and binding studies of the 20 S proteasome by NMR. Nature 445:618–622 (London, UK)PubMedCrossRefGoogle Scholar
  30. 30.
    Stockman BJ, Dalvit C (2002) NMR screening techniques in drug discovery and drug design. Prog Nucl Magn Reson Spectrosc 41:187–231CrossRefGoogle Scholar
  31. 31.
    Tugarinov V, Kay LE (2003) Ile, leu, and val methyl assignments of the 723-residue malate synthase g using a new labeling strategy and novel NMR methods. J Am Chem Soc 125:13868–13878PubMedCrossRefGoogle Scholar
  32. 32.
    Tugarinov V, Kay LE (2004) An isotope labeling strategy for methyl TROSY spectroscopy. J Biomol NMR 28:165–172PubMedCrossRefGoogle Scholar
  33. 33.
    Wishart D (2005) NMR spectroscopy and protein structure determination: applications to drug discovery and development. Curr Pharm Biotechnol 6:105–120PubMedCrossRefGoogle Scholar
  34. 34.
    Zartler ER, Shapiro MJ (2006) Protein NMR-based screening in drug discovery. Curr Pharm Des 12:3963–3972PubMedCrossRefGoogle Scholar
  35. 35.
    Zawadzke LE, Norcia M, Desbonnet CR et al (2008) Identification of an inhibitor of the MurC enzyme, which catalyzes an essential step in the peptidoglycan precursor synthesis pathway. Assay Drug Dev Technol 6:95–103PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Infection Discovery, AstraZeneca Pharmaceuticals LPWalthamUSA

Personalised recommendations